Treatment options and considerations for acquired resistance in EGFR mutation-positive non-small-cell lung cancer

Key Points

• Acquired resistance in EGFR mutation-positive non-small-cell lung cancer impacts treatment efficacy and survival rates.
• Observational analysis highlights that about 50% of patients may develop resistance to standard therapies within 12 months.
• Assessment using genomic profiling reveals key biomarkers for monitoring treatment response and resistance mechanisms.
• Findings suggest the need for personalized treatment strategies and ongoing monitoring to improve patient outcomes.